Evaluation of Matrix Metalloproteinase 9 Serum Concentration as a Biomarker in Malignant Mesothelioma

Table 3

Association of MMP9 SNPs with serum MMP9 levels before treatment.

Genotype	(%)	Serum MMP9 (ng/ml); Median (27%-75%)
rs17576 c.836A>G, p.Gln279Arg			0.041^a
AA	45 (41.7) [2]	669.8 (429.4-973.2)	Reference
AG	55 (50.9)	698.5 (530.2-1244.5)	0.139
GG	8 (7.4)	1313.6 (689.4-1591.6)	0.013
AG+GG	63 (58.3)	869.6 (546.1-1420.2)	0.053
rs2250889 c.1721C>G, p.Arg574Pro
CC	99 (91.7) [2]	753.8 (530.2-1219.1)	Reference
CG	9 (8.3)	503.0 (430.0-1084.7)	0.232
rs17577 c.2003G>A, p.Arg668Gln			0.146^a
GG	76 (69.7) [1]	661.8 (435.9-1130.8)	Reference
GA	30 (27.5)	1035.5 (538.6-1411.7)	0.187
AA	2 (2.8)	1207.2 (820.4-1207.2)	0.120
GA+AA	32 (30.3)	1053.5 (545.1-1414.5)	0.100
rs20544 c.3C>T			0.222^a
CC	18 (16.7) [2]	981.0 (558.0-1441.2)	Reference
CT	54 (50.0)	721.5 (493.9-1225.5)	0.275
TT	36 (33.3)	687.7 (425.2-975.3)	0.093
CT+TT	90 (83.3)	702.1 (486.8-1176.1)	0.148

^aCalculated using the Kruskal-Wallis test comparing all three genotypes. Numbers in [] denote missing genotype data.